Medicines Law & Policy statement at WHO PABS negotiations (IGWG 5)

Co-chairs, Thank you for the opportunity to say a few words.  My comments address issues related to technology transfer (TT), a topic we have been...

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...

Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...

This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....

Fair Medicines Pricing requires addressing monopolies and increasing transparency in pharmaceutical markets

The 4th WHO Fair Pricing Forum took place from 6 - 8 February 2024. Ellen 't Hoen spoke at the opening plenary. Below are...

Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...

This post can also be downloaded as a PDF here. 1.      Introduction Scaling-up production of new vaccines to provide many billions of doses on a time-scale...

“This week, the medicines were not there”: What is at stake in the pandemic...

Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...

The new IP strategy of war-torn Ukraine should prioritise public health and national security

Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...

What is the ‘know-how gap’ problem and how might it impact scaling up production...

This entire article is also available as a PDF by clicking here. 1. Introduction. How relevant are concerns about intellectual property rights causing problems for...

Covid-19 intellectual property pool gaining support

While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should...

Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two...

According to an investigation by Follow the Money, a Dutch investigative journalism outlet, the European Commission restored the market exclusivity of Tecfidera, a multiple...